First Patient Adopting TAC-001 Has Been Announced By Tallac
In a phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumours, Tallac Therapeutics has reported that the first patient has...
Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream
Pfizer previously held out hope that Eucrisa would become the trendiest topical treatment for inflammatory skin conditions. However, the ointment never took off because...
FDA Continues To Deal With Issues With Expedited Clearance
The use of excessively fragile efficacy data and delays in sponsors' presenting living proof from post-approval trials, as well as the approval of some...
Test For Sterility of Cell Culture Using Ratio of NA To NAM
According to research, the ratio of nicotinic acid (NA) to nicotinamide (NAM) considerably rises when living microorganisms are present inside 24 hours. This ratio...
Authorities Agree To Work Together Towards Integrating RWE
Real-world evidence (RWE) should be included in regulatory decision-making, according to a declaration backed by both the US Food and Drug Administration (FDA) and...
NHS Lays Long COVID Action Plan For Many With Chronic Signs
Instead of having patients return to their GP office for a variety of tests, lengthy COVID specialist clinics will now be able to refer...
Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19
Pfizer is prepared and equipped to continue its pandemic sales supremacy, the company's chief executive said on a July 28 investor call, even if federal...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...